Article

Aortic Stenosis in End-Stage Renal Disease: Incidence, Prevalence, and Mortality in a National Korean Cohort

Minjeong Kim[1,2], Min Ho Kim, Hyangkyoung Kim[1]

Supplementary Table S1. Annual incidence rate and prevalence (%) of AS in ESRD patients in Korea (2009–2021).

Year	Incidence rate (per 10,000 PY)	Prevalence (%)
2012	13.26	0.23
2013	16.07	0.26
2014	16.29	0.29
2015	19.3	0.33
2016	25.18	0.41
2017	21.46	0.41
2018	26.14	0.51
2019	28.73	0.58
2020	33.66	0.66
2021	35.31	0.77

ESRD: end-stage renal disease; AS: aortic stenosis.

Supplement Table S2. Sex-specific incidence rate and prevalence (%) of AS in ESRD patients in Korea (2009–2021).

Year	Male Incidence rate (per 10,000 PY)	Male Prevalence (%)	Female Incidence rate (per 10,000 PY)	Female Prevalence (%)
2012	13.23	0.24	13.29	0.23
2013	15.94	0.24	16.24	0.28
2014	17.36	0.28	14.82	0.29
2015	20.25	0.32	17.96	0.34
2016	26.18	0.41	23.75	0.40
2017	22.07	0.41	20.57	0.42
2018	26.80	0.51	25.18	0.51
2019	30.37	0.60	26.37	0.55
2020	33.59	0.67	33.77	0.64
2021	32.64	0.73	39.19	0.84

ESRD: end-stage renal disease; AS: aortic stenosis.

Supplement Table S3. Age-specific incidence rate and prevalence (%) of AS in ESRD patients in Korea (2009–2021).

Incidence/10,000										
Age Group	**2012**	**2013**	**2014**	**2015**	**2016**	**2017**	**2018**	**2019**	**2020**	**2021**
<50	5.44	4.39	5.99	5.01	2.44	5.64	7.99	3.95	8.62	10.58
50–59	9.42	12.51	9.72	13.88	17.77	12.13	16.19	20.15	24.81	18.87
60–69	15.11	18.74	16.65	23.43	27.41	22.60	29.32	33.16	35.25	36.69
70–79	22.99	28.43	24.52	32.95	48.50	36.60	43.76	45.07	51.17	51.31
≥80	21.98	22.09	51.52	25.26	35.75	41.07	35.10	41.56	48.13	64.15

Prevalence/10,000										
<50	7.25	9.67	9.41	9.18	8.14	7.25	12.00	8.68	16.45	18.71
50–59	21.20	18.40	21.53	23.79	28.56	26.09	35.27	40.30	46.31	47.73
60–69	26.86	28.11	31.13	37.75	47.07	51.80	60.69	68.69	77.91	90.90
70–79	38.67	46.44	42.90	55.20	75.03	67.67	79.27	94.29	93.44	112.67
≥80	26.37	36.82	66.67	55.57	46.27	60.71	67.16	71.43	87.31	108.64

ESRD: end-stage renal disease; AS: aortic stenosis.

Supplement Table S4. Age- and sex-specific incidence rate and prevalence (%) of AS in ESRD patients in Korea (2009–2021).

Incidence/10,000										
Age Group	**Sex**	**2012**	**2013**	**2014**	**2015**	**2016**	**2017**	**2018**	**2019**	**2020**	**2021**
<50	**Male**	5.44	4.39	5.99	5.01	2.44	5.64	7.99	3.95	8.62	10.58
<50	**Female**	7.25	9.67	9.41	9.18	8.14	7.25	12.00	8.68	16.45	18.71
50–59	**Male**	9.42	12.51	9.72	13.88	17.77	12.13	16.19	20.15	24.81	18.87
50–59	**Female**	21.20	18.40	21.53	23.79	28.56	26.09	35.27	40.30	46.31	47.73
60–69	**Male**	15.11	18.74	16.65	23.43	27.41	22.60	29.32	33.16	35.25	36.69
60–69	**Female**	26.86	28.11	31.13	37.75	47.07	51.80	60.69	68.69	77.91	90.90
70–79	**Male**	22.99	28.43	24.52	32.95	48.50	36.60	43.76	45.07	51.17	51.31
70–79	**Female**	38.67	46.44	42.90	55.20	75.03	67.67	79.27	94.29	93.44	112.67
≥80	**Male**	21.98	22.09	51.52	25.26	35.75	41.07	35.10	41.56	48.13	64.15
≥80	**Female**	26.37	36.82	66.67	55.57	46.27	60.71	67.16	71.43	87.31	108.64
Prevalence/10,000											
<50	**Male**	3.76	5.01	4.88	4.75	4.21	3.73	6.21	4.49	8.52	9.69
<50	**Female**	3.49	4.66	4.53	4.43	3.99	3.52	5.79	4.19	7.93	9.02
50–59	**Male**	10.99	9.53	11.16	12.33	14.80	13.52	18.27	20.84	23.92	24.73
50–59	**Female**	10.21	8.87	10.37	11.46	13.75	12.57	16.99	19.46	22.39	23.00
60–69	**Male**	13.90	14.62	16.17	19.60	24.45	26.83	31.46	35.56	40.31	46.99
60–69	**Female**	12.94	13.61	15.06	18.25	22.73	24.97	29.23	33.13	37.60	43.91
70–79	**Male**	20.09	24.03	22.19	28.53	38.75	34.96	40.99	48.79	48.42	58.32
70–79	**Female**	18.58	22.23	20.51	26.37	35.78	32.71	38.28	45.50	45.02	54.35
≥80	**Male**	13.65	19.73	35.54	29.01	24.00	31.46	34.77	36.99	45.23	56.21
≥80	**Female**	12.77	18.44	33.11	27.02	22.35	29.29	32.39	34.47	42.08	52.43

ESRD: end-stage renal disease; AS: aortic stenosis.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.